Literature DB >> 1482129

Characterization of an azole-resistant Candida glabrata isolate.

H vanden Bossche1, P Marichal, F C Odds, L Le Jeune, M C Coene.   

Abstract

A Candida (Torulopsis) glabrata strain (B57149) became resistant to fluconazole after a patient carrying the organism was treated with the drug at 400 mg once daily for 9 days. Growth of the pretreatment isolate (B57148) was inhibited by 50% with 0.67 microM ketoconazole, 1.0 microM itraconazole, and 43 microM fluconazole, whereas growth of B57149 was inhibited slightly by 10 microM ketoconazole but was unaffected by 10 microM itraconazole or 100 microM fluconazole. This indicates cross-resistance to all three azole antifungal agents. The cellular fluconazole content of B57149 was from 1.5- to 3-fold lower than that of B57148, suggesting a difference in drug uptake between the strains. However, this difference was smaller than the measured difference in susceptibility and, therefore, cannot fully explain the fluconazole resistance of B57149. Moreover, the intracellular contents of ketoconazole and itraconazole differed by less than twofold between the strains, so that uptake differences did not account for the azole cross-resistance of B57149. The microsomal cytochrome P-450 content of B57149 was about twice that of B57148, a difference quantitatively similar to the increased subcellular ergosterol synthesis from mevalonate or lanosterol. These results indicate that the level of P-450-dependent 14 alpha-demethylation of lanosterol is higher in B57149. Increased ergosterol synthesis was also seen in intact B57149 cells, and this coincided with a decreased susceptibility of B57149 toward all three azoles and amphotericin B. B57149 also had higher squalene epoxidase activity, and thus, more terbinafine was needed to inhibit the synthesis of 2,3-oxidosqualene from squalene. P-450 content and ergosterol synthesis both decreased when isolate B57149 was subcultured repeatedly on drug-free medium. This repeated subculture also fully restored the strain's itraconazole susceptibility, but only partly increased its susceptibility to fluconazole. The results suggest that both lower fluconazole uptake and increased P-450-dependent ergosterol synthesis are involved in the mechanism of fluconazole resistance but that only the increased ergosterol synthesis contributes to itraconazole cross-resistance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1482129      PMCID: PMC245514          DOI: 10.1128/AAC.36.12.2602

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  [Resistance to fluconazole in hospitalized patients. Concordance between Candida albicans resistance in vitro and therapeutic failure].

Authors:  J Dupouy-Camet; A Paugam; C Di Donato; C Viguié; I Vicens; P J Volle; C Tourte-Schaefer
Journal:  Presse Med       Date:  1991-09-14       Impact factor: 1.228

Review 2.  Molecular genetic studies on the mode of action of azole antifungal agents.

Authors:  S L Kelly; J Rowe; P F Watson
Journal:  Biochem Soc Trans       Date:  1991-08       Impact factor: 5.407

Review 3.  Mutation in cytochrome P-450-dependent 14 alpha-demethylase results in decreased affinity for azole antifungals.

Authors:  H Vanden Bossche; P Marichal; J Gorrens; D Bellens; H Moereels; P A Janssen
Journal:  Biochem Soc Trans       Date:  1990-02       Impact factor: 5.407

4.  Isolation of the gene for cytochrome P450L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans.

Authors:  D R Kirsch; M H Lai; J O'Sullivan
Journal:  Gene       Date:  1988-09-07       Impact factor: 3.688

5.  Miconazole-resistant Candida.

Authors:  R J Holt; A Azmi
Journal:  Lancet       Date:  1978-01-07       Impact factor: 79.321

6.  Inhibition of 14 alpha-sterol demethylase activity in Candida albicans Darlington does not correlate with resistance to azole.

Authors:  C A Hitchcock; K J Barrett-Bee; N J Russell
Journal:  J Med Vet Mycol       Date:  1987-10

7.  Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients.

Authors:  C R Horsburgh; C H Kirkpatrick
Journal:  Am J Med       Date:  1983-01-24       Impact factor: 4.965

8.  Isolation of a cytochrome P-450 structural gene from Saccharomyces cerevisiae.

Authors:  V F Kalb; J C Loper; C R Dey; C W Woods; T R Sutter
Journal:  Gene       Date:  1986       Impact factor: 3.688

9.  Targeted selection of recombinant clones through gene dosage effects.

Authors:  J Rine; W Hansen; E Hardeman; R W Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

Review 10.  Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action.

Authors:  H Vanden Bossche
Journal:  Curr Top Med Mycol       Date:  1985
View more
  72 in total

Review 1.  Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.

Authors:  M A Ghannoum; L B Rice
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

Review 2.  Mechanisms of fungal resistance: an overview.

Authors:  Maher M Balkis; Steven D Leidich; Pranab K Mukherjee; Mahmoud A Ghannoum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

Review 4.  Genomics and antimicrobial drug discovery.

Authors:  D T Moir; K J Shaw; R S Hare; G F Vovis
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

5.  Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice.

Authors:  J Brieland; D Essig; C Jackson; D Frank; D Loebenberg; F Menzel; B Arnold; B DiDomenico; R Hare
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

6.  In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.

Authors:  Jason Cota; Michael Carden; John R Graybill; Laura K Najvar; David S Burgess; Nathan P Wiederhold
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 7.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

8.  In vitro activity of a new antifungal triazole, D0870, against Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus.

Authors:  F Barchiesi; A L Colombo; D A McGough; A W Fothergill; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

9.  Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay.

Authors:  B Jahn; E Martin; A Stueben; S Bhakdi
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

10.  Investigation of the Sterol Composition and Azole Resistance in Field Isolates of Septoria tritici.

Authors:  T Joseph-Horne; D Hollomon; N Manning; S L Kelly
Journal:  Appl Environ Microbiol       Date:  1996-01       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.